| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Lorpiprazole | hsa00030 | Pentose phosphate pathway | 9.38E-07 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Lorpiprazole | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | | | Lorpiprazole | hsa00051 | Fructose and mannose metabolism | 4.00E-02 | 2 | P60174, P04075 | TPI1, ALDOA | More | | | Lorpiprazole | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | | Lorpiprazole | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | | Lorpiprazole | hsa00220 | Arginine biosynthesis | 1.26E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | | Lorpiprazole | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | | Lorpiprazole | hsa00310 | Lysine degradation | 4.57E-02 | 2 | Q96KQ7, Q02809 | EHMT2, PLOD1 | More | | | Lorpiprazole | hsa00350 | Tyrosine metabolism | 3.40E-02 | 1 | P28332 | ADH6 | More | | | Lorpiprazole | hsa00500 | Starch and sucrose metabolism | 6.15E-08 | 4 | O43451, P46976, P35573, P06737 | MGAM, GYG1, AGL, PYGL | More | | | Lorpiprazole | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Lorpiprazole | hsa00562 | Inositol phosphate metabolism | 1.78E-03 | 4 | P27987, P19174, P42338, Q02252 | ITPKB, PLCG1, PIK3CB, ALDH6A1 | More | | | Lorpiprazole | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Lorpiprazole | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Lorpiprazole | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | | Lorpiprazole | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.03E-04 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Lorpiprazole | hsa00730 | Thiamine metabolism | 1.06E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Lorpiprazole | hsa00770 | Pantothenate and CoA biosynthesis | 4.29E-04 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Lorpiprazole | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | | | Lorpiprazole | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | | Lorpiprazole | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | | Lorpiprazole | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | | Lorpiprazole | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.26E-05 | 4 | P78417, P28332, P09211, P11712 | GSTO1, ADH6, GSTP1, CYP2C9 | More | | | Lorpiprazole | hsa00982 | Drug metabolism - cytochrome P450 | 8.40E-04 | 3 | P11712, P78417, P28332 | CYP2C9, GSTO1, ADH6 | More | | | Lorpiprazole | hsa00983 | Drug metabolism - other enzymes | 2.42E-03 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Lorpiprazole | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | | Lorpiprazole | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Lorpiprazole | hsa01230 | Biosynthesis of amino acids | 3.06E-05 | 5 | P51854, P60891, P05089, P15104, P37837 | TKTL1, PRPS1, ARG1, GLUL, TALDO1 | More | | | Lorpiprazole | hsa01240 | Biosynthesis of cofactors | 2.01E-03 | 4 | P13716, Q9BQB6, P14550, P14618 | ALAD, VKORC1, AKR1A1, PKM2 | More | | | Lorpiprazole | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa01522 | Endocrine resistance | 1.69E-02 | 4 | P22694, P08069, P10415, Q13323 | PRKACB, IGF1R, BCL2, BIK | More | | | Lorpiprazole | hsa01523 | Antifolate resistance | 2.09E-03 | 5 | P41440, Q92820, P04818, P01375, P18054 | SLC19A1, GGH, TYMS, TNF, ALOX12 | More | | | Lorpiprazole | hsa02010 | ABC transporters | 1.98E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | | Lorpiprazole | hsa03010 | Ribosome | 1.13E-06 | 12 | P26373, P42677, P40429, P62917, P46776, Q9H0U6, Q07020, Q02878, P27635, P05386, P62249, P23396 | RPL13, RPS27, RPL13A, RPL8, RPL27A, MRPL18, RPL18, RPL6, RPL10, RPLP1, RPS16, RPS3 | More | | | Lorpiprazole | hsa03013 | RNA transport | 4.09E-02 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | | Lorpiprazole | hsa03020 | RNA polymerase | 5.61E-04 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | | Lorpiprazole | hsa03022 | Basal transcription factors | 2.68E-04 | 3 | O00268, Q5H9L4, Q15544 | TAF4, TAF7L, TAF11 | More | | | Lorpiprazole | hsa03040 | Spliceosome | 2.05E-03 | 9 | Q14562, O43143, O60508, P08579, Q07955, Q01130, Q13243, P11142, O43447 | DHX8, DHX15, CDC40, SNRPB2, SFRS1, SFRS2, SFRS5, HSPA8, PPIH | More | | | Lorpiprazole | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | | Lorpiprazole | hsa03320 | PPAR signaling pathway | 5.20E-04 | 4 | Q6PCB7, O00767, Q9UNU6, Q02318 | SLC27A1, SCD, CYP8B1, CYP27A1 | More | | | Lorpiprazole | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | | Lorpiprazole | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | | Lorpiprazole | hsa03460 | Fanconi anemia pathway | 1.85E-02 | 2 | P40692, Q9UNA4 | MLH1, POLI | More | | | Lorpiprazole | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04012 | ErbB signaling pathway | 1.15E-03 | 6 | Q13153, P16333, Q13191, P17252, P19174, P42338 | PAK1, NCK1, CBLB, PRKCA, PLCG1, PIK3CB | More | | | Lorpiprazole | hsa04014 | Ras signaling pathway | 4.81E-04 | 11 | P42338, P20827, P49767, P08069, Q13009, P17252, P14921, P0DP23, P62873, P50151, P19174 | PIK3CB, EFNA1, VEGFC, IGF1R, TIAM1, PRKCA, ETS1, CALM1, GNB1, GNG10, PLCG1 | More | | | Lorpiprazole | hsa04015 | Rap1 signaling pathway | 3.18E-03 | 9 | P20827, P49767, P08069, P11215, Q13009, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, IGF1R, ITGAM, TIAM1, PIK3CB, CALM1, PRKCA, PLCG1 | More | | | Lorpiprazole | hsa04020 | Calcium signaling pathway | 4.34E-02 | 6 | P27987, P17252, O15399, P19174, P0DP23, P49767 | ITPKB, PRKCA, GRIN2D, PLCG1, CALM1, VEGFC | More | | | Lorpiprazole | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | | Lorpiprazole | hsa04024 | cAMP signaling pathway | 1.39E-02 | 7 | P42338, P0DP23, Q13370, O15399, P25963, Q13009, Q13153 | PIK3CB, CALM1, PDE3B, GRIN2D, NFKBIA, TIAM1, PAK1 | More | | | Lorpiprazole | hsa04060 | Cytokine-cytokine receptor interaction | 3.17E-05 | 16 | P14784, P27930, P14778, P26842, Q06643, Q13651, Q9HBE5, P25024, P25025, Q9UBD3, P47992, P09341, P19875, P18510, P01730, Q93038 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, IL21R, CXCR1, CXCR2, XCL2, XCL1, CXCL1, CXCL2, IL1RN, CD4, TNFRSF25 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P24723 | PRKCH | Protein kinase C eta type | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.876 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.895 | | P06239 | LCK | Tyrosine-protein kinase Lck | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.923 | | P24723 | PRKCH | Protein kinase C eta type | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.705 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P26842 | CD27 | CD27 antigen | -0.712 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26842 | CD27 | CD27 antigen | 0.817 | | P24723 | PRKCH | Protein kinase C eta type | Q06643 | LTB | Lymphotoxin-beta | 0.763 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | -0.713 | | P24723 | PRKCH | Protein kinase C eta type | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.747 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.881 | | P24723 | PRKCH | Protein kinase C eta type | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.776 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 0.843 | | P06239 | LCK | Tyrosine-protein kinase Lck | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.892 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.796 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.715 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P47992 | XCL1 | Lymphotactin | -0.796 | | P06239 | LCK | Tyrosine-protein kinase Lck | P47992 | XCL1 | Lymphotactin | 0.715 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | | P24723 | PRKCH | Protein kinase C eta type | P09341 | CXCL1 | Growth-regulated alpha protein | -0.707 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | | P24723 | PRKCH | Protein kinase C eta type | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.853 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P18510 | IL1RN | Interleukin-1 receptor antagonist protein | 0.841 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P24723 | PRKCH | Protein kinase C eta type | Q93038 | TNFRSF25 | Tumor necrosis factor receptor superfamily member 25 | 0.761 |
| | Lorpiprazole | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.48E-04 | 8 | P09341, P25024, P02775, P25025, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, PPBP, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | | Lorpiprazole | hsa04062 | Chemokine signaling pathway | 7.18E-06 | 18 | P25024, P25025, P09341, P47992, Q9UBD3, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q08881, Q13009, P14598, P42224, P25963, P49841 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, ITK, TIAM1, NCF1, STAT1, NFKBIA, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 0.843 | | P06239 | LCK | Tyrosine-protein kinase Lck | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.892 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P47992 | XCL1 | Lymphotactin | -0.796 | | P06239 | LCK | Tyrosine-protein kinase Lck | P47992 | XCL1 | Lymphotactin | 0.715 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.796 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.715 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.749 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.736 | | P06239 | LCK | Tyrosine-protein kinase Lck | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.728 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.754 | | P06239 | LCK | Tyrosine-protein kinase Lck | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.71 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P43250 | GRK6 | G protein-coupled receptor kinase 6 | -0.701 | | P06239 | LCK | Tyrosine-protein kinase Lck | P43250 | GRK6 | G protein-coupled receptor kinase 6 | -0.702 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.709 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | -0.792 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14598 | NCF1 | Neutrophil cytosol factor 1 | 0.908 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.798 |
| | Lorpiprazole | hsa04064 | NF-kappa B signaling pathway | 1.48E-12 | 24 | P10415, Q13489, P25963, P51617, O00463, P14778, P01584, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9NQC7 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, IL1R1, IL1B, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, CYLD | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P05164 | MPO | Myeloperoxidase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.81 | | P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | | P08246 | ELA2 | Neutrophil elastase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.716 | | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.786 | | Q04759 | PRKCQ | Protein kinase C theta type | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.81 | | P05164 | MPO | Myeloperoxidase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.821 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.923 | | P24723 | PRKCH | Protein kinase C eta type | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.705 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P05164 | MPO | Myeloperoxidase | Q04759 | PRKCQ | Protein kinase C theta type | -0.88 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | | P05164 | MPO | Myeloperoxidase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.758 | | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | | P08246 | ELA2 | Neutrophil elastase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.725 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.82 | | Q04759 | PRKCQ | Protein kinase C theta type | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.76 | | P05164 | MPO | Myeloperoxidase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.782 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | | P08246 | ELA2 | Neutrophil elastase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.766 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.749 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | | P05164 | MPO | Myeloperoxidase | Q13315 | ATM | Serine-protein kinase ATM | -0.725 | | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.756 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.793 | | Q04759 | PRKCQ | Protein kinase C theta type | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.846 | | P05164 | MPO | Myeloperoxidase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.812 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | | P08246 | ELA2 | Neutrophil elastase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.7 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | | Q04759 | PRKCQ | Protein kinase C theta type | P09341 | CXCL1 | Growth-regulated alpha protein | -0.885 | | P24723 | PRKCH | Protein kinase C eta type | P09341 | CXCL1 | Growth-regulated alpha protein | -0.707 | | P05164 | MPO | Myeloperoxidase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.806 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | | P24723 | PRKCH | Protein kinase C eta type | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.853 | | P24723 | PRKCH | Protein kinase C eta type | Q06643 | LTB | Lymphotoxin-beta | 0.763 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.825 |
| | Lorpiprazole | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04070 | Phosphatidylinositol signaling system | 2.95E-04 | 8 | P19174, P0DP23, P42338, P23743, Q86XP1, P27987, Q96DU7, P17252 | PLCG1, CALM1, PIK3CB, DGKA, DGKH, ITPKB, ITPKC, PRKCA | More | | | Lorpiprazole | hsa04071 | Sphingolipid signaling pathway | 3.82E-05 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | | Lorpiprazole | hsa04080 | Neuroactive ligand-receptor interaction | 2.43E-06 | 10 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1, ADRB2 | More | | | Lorpiprazole | hsa04114 | Oocyte meiosis | 2.95E-05 | 6 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0, P08069 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | | | Lorpiprazole | hsa04115 | p53 signaling pathway | 3.32E-03 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | | Lorpiprazole | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Lorpiprazole | hsa04137 | Mitophagy - animal | 1.41E-03 | 3 | P67870, P19532, P18848 | CSNK2B, TFE3, ATF4 | More | | | Lorpiprazole | hsa04140 | Autophagy - animal | 1.91E-03 | 8 | P08069, Q9Y4H2, P42338, Q9NQL2, P22694, Q14643, P10415, Q04759 | IGF1R, IRS2, PIK3CB, RRAGD, PRKACB, ITPR1, BCL2, PRKCQ | More | | | Lorpiprazole | hsa04142 | Lysosome | 2.45E-03 | 9 | Q99437, P25774, P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | ATP6V0B, CTSS, HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | | Lorpiprazole | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | | | Lorpiprazole | hsa04145 | Phagosome | 7.50E-03 | 10 | Q15080, P14598, Q13509, Q13488, Q99437, P05164, O60603, P35443, P13765, P25774 | NCF4, NCF1, TUBB3, TCIRG1, ATP6V0B, MPO, TLR2, THBS4, HLA-DOB, CTSS | More | | | Lorpiprazole | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04151 | PI3K-Akt signaling pathway | 5.43E-04 | 19 | P62753, P42338, O43521, P27348, P20827, P49767, P08238, Q8WYR1, P62873, P50151, P16144, O15335, Q13751, P14784, P01568, P18848, P17252, O00141, Q6ZUJ8 | RPS6, PIK3CB, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNB1, GNG10, ITGB4, CHAD, LAMB3, IL2RB, IFNA21, ATF4, PRKCA, SGK, PIK3AP1 | More | | | Lorpiprazole | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04210 | Apoptosis | 1.33E-04 | 14 | Q13315, P10415, Q13489, O76075, P25963, P01375, O75460, P24522, Q16548, Q13077, O43521, P43234, P18848, Q14643 | ATM, BCL2, BIRC3, DFFB, NFKBIA, TNF, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, CTSO, ATF4, ITPR1 | More | | | Lorpiprazole | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04213 | Longevity regulating pathway - multiple species | 3.78E-04 | 8 | P42338, P08069, Q9Y4H2, Q08828, P51828, P0DMV8, P11142, Q13547 | PIK3CB, IGF1R, IRS2, ADCY1, ADCY7, HSPA1A, HSPA8, HDAC1 | More | | | Lorpiprazole | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | | Lorpiprazole | hsa04217 | Necroptosis | 8.20E-05 | 15 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q99878, Q9H444, O43633 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, CHMP4B, CHMP2A | More | | | Lorpiprazole | hsa04218 | Cellular senescence | 2.35E-02 | 4 | P30281, P01889, P10321, P12236 | CCND3, HLA-B, HLA-C, SLC25A6 | More | | | Lorpiprazole | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | | Lorpiprazole | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | | Lorpiprazole | hsa04340 | Hedgehog signaling pathway | 9.74E-03 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | | Lorpiprazole | hsa04360 | Axon guidance | 2.13E-03 | 7 | P16333, P20827, O95631, P17252, P42338, P23528, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, CFL1, PLCG1 | More | | | Lorpiprazole | hsa04370 | VEGF signaling pathway | 6.08E-08 | 6 | P19174, P16298, P42338, P17252, Q05397, Q02750 | PLCG1, PPP3CB, PIK3CB, PRKCA, PTK2, MAP2K1 | More | | | Lorpiprazole | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | | Lorpiprazole | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | | Lorpiprazole | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | | | Lorpiprazole | hsa04510 | Focal adhesion | 2.69E-03 | 10 | P16144, O75369, P42338, Q15942, P17252, O15335, Q13751, Q13489, P08069, P49767 | ITGB4, FLNB, PIK3CB, ZYX, PRKCA, CHAD, LAMB3, BIRC3, IGF1R, VEGFC | More | | | Lorpiprazole | hsa04512 | ECM-receptor interaction | 1.90E-02 | 2 | P26012, P16070 | ITGB8, CD44 | More | | | Lorpiprazole | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04530 | Tight junction | 2.45E-03 | 6 | Q8TEU7, P16989, P56750, O00501, Q14247, P24844 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN, MYL9 | More | | | Lorpiprazole | hsa04540 | Gap junction | 2.86E-02 | 3 | P22694, P68371, Q14643 | PRKACB, TUBB2C, ITPR1 | More | | | Lorpiprazole | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 9.61E-03 | 4 | Q13873, Q02750, P08069, Q86SE9 | BMPR2, MAP2K1, IGF1R, PCGF5 | More | | | Lorpiprazole | hsa04610 | Complement and coagulation cascades | 5.18E-06 | 1 | P0C0L4 | C4A | More | | | Lorpiprazole | hsa04612 | Antigen processing and presentation | 1.88E-08 | 13 | P13765, P48382, P01730, Q14953, P26715, P26717, Q07444, Q13241, O43908, P01732, P30101, P11142, P01375 | HLA-DOB, RFX5, CD4, KIR2DS5, KLRC1, KLRC2, KLRC3, KLRD1, KLRC4, CD8A, PDIA3, HSPA8, TNF | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P05164 | MPO | Myeloperoxidase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.85 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P01375 | TNF | Tumor necrosis factor | P48382 | RFX5 | DNA-binding protein RFX5 | -0.796 | | P05164 | MPO | Myeloperoxidase | P48382 | RFX5 | DNA-binding protein RFX5 | -0.851 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | P01375 | TNF | Tumor necrosis factor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.814 | | Q04759 | PRKCQ | Protein kinase C theta type | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.803 | | P05164 | MPO | Myeloperoxidase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | | P01375 | TNF | Tumor necrosis factor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.814 | | Q04759 | PRKCQ | Protein kinase C theta type | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.803 | | P05164 | MPO | Myeloperoxidase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P24723 | PRKCH | Protein kinase C eta type | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.723 | | P01375 | TNF | Tumor necrosis factor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.769 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.849 | | P24723 | PRKCH | Protein kinase C eta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.768 | | P05164 | MPO | Myeloperoxidase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.775 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | P01375 | TNF | Tumor necrosis factor | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.809 | | Q04759 | PRKCQ | Protein kinase C theta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.861 | | P24723 | PRKCH | Protein kinase C eta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.838 | | P05164 | MPO | Myeloperoxidase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | | P24723 | PRKCH | Protein kinase C eta type | P30101 | PDIA3 | Protein disulfide-isomerase A3 | 0.751 | | P24723 | PRKCH | Protein kinase C eta type | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.715 | | P01375 | TNF | Tumor necrosis factor | P01375 | TNF | Tumor necrosis factor | 1 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 |
| | Lorpiprazole | hsa04613 | Neutrophil extracellular trap formation | 2.55E-05 | 20 | P17252, O60603, P05164, P08246, Q9UM07, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1, AQP9, MAPK14 | More | | | Lorpiprazole | hsa04621 | NOD-like receptor signaling pathway | 2.63E-05 | 16 | Q14643, P25963, Q13489, P10599, Q9H1Y0, P43490, O00463, P10415, P29728, Q05823, P01375, P09341, P49913, P59665, P59666, P12838 | ITPR1, NFKBIA, BIRC3, TXN, ATG5, PBEF1, TRAF5, BCL2, OAS2, RNASEL, TNF, CXCL1, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | | Lorpiprazole | hsa04623 | Cytosolic DNA-sensing pathway | 1.35E-03 | 4 | P01584, P01568, P25963, Q8NHW4 | IL1B, IFNA21, NFKBIA, CCL4L2 | More | | | Lorpiprazole | hsa04625 | C-type lectin receptor signaling pathway | 8.18E-03 | 5 | Q9ULY5, Q13153, P20749, P01375, Q16539 | CLEC4E, PAK1, BCL3, TNF, MAPK14 | More | | | Lorpiprazole | hsa04640 | Hematopoietic cell lineage | 1.92E-08 | 13 | P13612, P14778, P27930, P11215, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ITGAM, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P13612 | ITGA4 | Integrin alpha-4 | -0.801 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13612 | ITGA4 | Integrin alpha-4 | 0.732 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.923 | | P24723 | PRKCH | Protein kinase C eta type | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.705 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.895 | | Q04759 | PRKCQ | Protein kinase C theta type | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.733 | | P06239 | LCK | Tyrosine-protein kinase Lck | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.779 | | P24723 | PRKCH | Protein kinase C eta type | P11215 | ITGAM | Integrin alpha-M | -0.7 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P11836 | MS4A1 | B-lymphocyte antigen CD20 | -0.704 | | Q04759 | PRKCQ | Protein kinase C theta type | P25063 | CD24 | Signal transducer CD24 | -0.903 | | P24723 | PRKCH | Protein kinase C eta type | P25063 | CD24 | Signal transducer CD24 | -0.838 | | P06239 | LCK | Tyrosine-protein kinase Lck | P25063 | CD24 | Signal transducer CD24 | -0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.759 | | Q04759 | PRKCQ | Protein kinase C theta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.861 | | P24723 | PRKCH | Protein kinase C eta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.838 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P24723 | PRKCH | Protein kinase C eta type | P09564 | CD7 | T-cell antigen CD7 | 0.865 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09564 | CD7 | T-cell antigen CD7 | 0.84 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.738 | | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 |
| | Lorpiprazole | hsa04650 | Natural killer cell mediated cytotoxicity | 2.02E-16 | 19 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13153, Q13241, P26718, O14931, O75015, P26717, Q07444, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, PAK1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q05397 | PTK2 | Focal adhesion kinase 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.919 | | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.774 | | Q05397 | PTK2 | Focal adhesion kinase 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.849 | | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.9 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P01375 | TNF | Tumor necrosis factor | P01375 | TNF | Tumor necrosis factor | 1 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.807 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.718 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | P01375 | TNF | Tumor necrosis factor | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.717 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.799 | | Q04759 | PRKCQ | Protein kinase C theta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.855 | | P24723 | PRKCH | Protein kinase C eta type | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.835 | | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.764 | | P01375 | TNF | Tumor necrosis factor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.727 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | | P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | Q05397 | PTK2 | Focal adhesion kinase 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.898 | | Q6PCB7 | SLC27A1 | Long-chain fatty acid transport protein 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.799 | | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | | P01375 | TNF | Tumor necrosis factor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.769 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.733 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.849 | | P24723 | PRKCH | Protein kinase C eta type | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.768 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | P01375 | TNF | Tumor necrosis factor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.754 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.888 | | Q04759 | PRKCQ | Protein kinase C theta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.918 | | P24723 | PRKCH | Protein kinase C eta type | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.822 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.803 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | | P24723 | PRKCH | Protein kinase C eta type | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.828 | | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | | P01375 | TNF | Tumor necrosis factor | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.838 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.712 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | | P01375 | TNF | Tumor necrosis factor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.814 | | Q04759 | PRKCQ | Protein kinase C theta type | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P24723 | PRKCH | Protein kinase C eta type | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.723 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | P01375 | TNF | Tumor necrosis factor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.814 | | Q04759 | PRKCQ | Protein kinase C theta type | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| | Lorpiprazole | hsa04657 | IL-17 signaling pathway | 1.46E-04 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | | Lorpiprazole | hsa04658 | Th1 and Th2 cell differentiation | 1.33E-20 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | Q04759 | PRKCQ | Protein kinase C theta type | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.746 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.714 | | Q04759 | PRKCQ | Protein kinase C theta type | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.867 | | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.867 | | Q04759 | PRKCQ | Protein kinase C theta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.843 | | P24723 | PRKCH | Protein kinase C eta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.856 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | | P24723 | PRKCH | Protein kinase C eta type | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.876 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.738 | | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.744 | | P24723 | PRKCH | Protein kinase C eta type | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.915 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
| | Lorpiprazole | hsa04659 | Th17 cell differentiation | 1.46E-18 | 20 | P25963, Q04759, Q16539, P19174, P01730, P06239, P42224, P14784, P13765, P14778, Q9HBE5, P40189, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL21R, IL6ST, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.865 | | P24723 | PRKCH | Protein kinase C eta type | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.876 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.738 | | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.923 | | P24723 | PRKCH | Protein kinase C eta type | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.705 | | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.909 | | Q04759 | PRKCQ | Protein kinase C theta type | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.8 | | P24723 | PRKCH | Protein kinase C eta type | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.776 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.748 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.867 | | Q04759 | PRKCQ | Protein kinase C theta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.843 | | P24723 | PRKCH | Protein kinase C eta type | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.856 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.714 | | Q04759 | PRKCQ | Protein kinase C theta type | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.867 | | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.802 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 |
| | Lorpiprazole | hsa04660 | T cell receptor signaling pathway | 1.27E-14 | 19 | P01375, P25963, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, Q13153, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, PAK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | | P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | P08246 | ELA2 | Neutrophil elastase | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | -0.854 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.727 | | Q04759 | PRKCQ | Protein kinase C theta type | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.733 | | P08246 | ELA2 | Neutrophil elastase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.724 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.709 | | Q04759 | PRKCQ | Protein kinase C theta type | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.803 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | | P08246 | ELA2 | Neutrophil elastase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.782 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.759 | | Q04759 | PRKCQ | Protein kinase C theta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.861 | | P24723 | PRKCH | Protein kinase C eta type | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.838 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.75 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.767 | | P24723 | PRKCH | Protein kinase C eta type | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.779 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.798 |
| | Lorpiprazole | hsa04662 | B cell receptor signaling pathway | 1.16E-05 | 6 | P49841, P42338, P60033, P07948, P21854, Q8N149 | GSK3B, PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Lorpiprazole | hsa04664 | Fc epsilon RI signaling pathway | 1.25E-04 | 8 | P01375, Q16539, P42338, P17252, Q9UQC2, P07948, P19174, P09917 | TNF, MAPK14, PIK3CB, PRKCA, GAB2, LYN, PLCG1, ALOX5 | More | | | Lorpiprazole | hsa04666 | Fc gamma R-mediated phagocytosis | 8.08E-03 | 5 | P42338, P19174, P23528, P14598, P17252 | PIK3CB, PLCG1, CFL1, NCF1, PRKCA | More | | | Lorpiprazole | hsa04668 | TNF signaling pathway | 1.99E-05 | 12 | P01375, O00463, Q13489, Q16539, P25963, P18848, P19875, P01584, P20749, Q13077, P14780, P20333 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, ATF4, CXCL2, IL1B, BCL3, TRAF1, MMP9, TNFRSF1B | More | | | Lorpiprazole | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | | Lorpiprazole | hsa04713 | Circadian entrainment | 1.24E-02 | 5 | O15399, P0DP23, P17252, P62873, P50151 | GRIN2D, CALM1, PRKCA, GNB1, GNG10 | More | | | Lorpiprazole | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Lorpiprazole | hsa04720 | Long-term potentiation | 1.84E-04 | 5 | P16298, Q15418, P51812, P18848, Q02750 | PPP3CB, RPS6KA1, RPS6KA3, ATF4, MAP2K1 | More | | | Lorpiprazole | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Lorpiprazole | hsa04724 | Glutamatergic synapse | 1.44E-04 | 6 | O15399, P17252, P62873, P63218, P50151, P15104 | GRIN2D, PRKCA, GNB1, GNG5, GNG10, GLUL | More | | | Lorpiprazole | hsa04725 | Cholinergic synapse | 6.87E-05 | 9 | P22694, Q14643, P17252, P62873, P63218, P50151, P18848, P42338, P10415 | PRKACB, ITPR1, PRKCA, GNB1, GNG5, GNG10, ATF4, PIK3CB, BCL2 | More | | | Lorpiprazole | hsa04726 | Serotonergic synapse | 2.54E-02 | 5 | P17252, P62873, P50151, P33260, P09917 | PRKCA, GNB1, GNG10, CYP2C18, ALOX5 | More | | | Lorpiprazole | hsa04727 | GABAergic synapse | 5.11E-04 | 5 | P62873, P63218, P50151, P15104, P17252 | GNB1, GNG5, GNG10, GLUL, PRKCA | More | | | Lorpiprazole | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | | Lorpiprazole | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Lorpiprazole | hsa04744 | Phototransduction | 1.67E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Lorpiprazole | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.93E-04 | 9 | P14778, P01584, Q08828, P51828, P19174, P42338, P24723, Q04759, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PLCG1, PIK3CB, PRKCH, PRKCQ, CALM1 | More | | | Lorpiprazole | hsa04913 | Ovarian steroidogenesis | 6.27E-04 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | | | Lorpiprazole | hsa04914 | Progesterone-mediated oocyte maturation | 8.55E-06 | 10 | P08069, Q17RY0, P42338, Q13370, Q9UJX4, Q9Y6D9, P30304, P08238, P51812, Q02750 | IGF1R, CPEB4, PIK3CB, PDE3B, ANAPC5, MAD1L1, CDC25A, HSP90AB1, RPS6KA3, MAP2K1 | More | | | Lorpiprazole | hsa04915 | Estrogen signaling pathway | 2.77E-03 | 10 | P14780, P22694, P18848, Q08828, P51828, P0DMV8, Q14643, P0DP23, Q15788, P10415 | MMP9, PRKACB, ATF4, ADCY1, ADCY7, HSPA1A, ITPR1, CALM1, NCOA1, BCL2 | More | | | Lorpiprazole | hsa04918 | Thyroid hormone synthesis | 1.26E-02 | 4 | P22694, P18848, Q14643, P05543 | PRKACB, ATF4, ITPR1, SERPINA7 | More | | | Lorpiprazole | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | | Lorpiprazole | hsa04922 | Glucagon signaling pathway | 4.18E-02 | 2 | P14618, P06737 | PKM2, PYGL | More | | | Lorpiprazole | hsa04924 | Renin secretion | 2.90E-04 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | | Lorpiprazole | hsa04926 | Relaxin signaling pathway | 2.34E-05 | 12 | P25963, P42338, P62873, P63218, P50151, P18848, P22694, P49767, P14780, P17252, P30679, P49407 | NFKBIA, PIK3CB, GNB1, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, PRKCA, GNA15, ARRB1 | More | | | Lorpiprazole | hsa04927 | Cortisol synthesis and secretion | 2.60E-05 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | | Lorpiprazole | hsa04928 | Parathyroid hormone synthesis, secretion and action | 6.95E-04 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | | Lorpiprazole | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | | Lorpiprazole | hsa04932 | Non-alcoholic fatty liver disease | 6.81E-07 | 12 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, P12074, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA5, NDUFC2, SDHD | More | | | Lorpiprazole | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.05E-03 | 8 | P84022, Q13485, P42224, P10415, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, BCL2, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | | Lorpiprazole | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | | | Lorpiprazole | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Lorpiprazole | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | | Lorpiprazole | hsa04966 | Collecting duct acid secretion | 1.29E-03 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | | Lorpiprazole | hsa04970 | Salivary secretion | 2.43E-05 | 8 | P07550, Q08828, P51828, P22694, Q14643, P17252, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, ITPR1, PRKCA, CALM1, CAMP | More | | | Lorpiprazole | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | | Lorpiprazole | hsa04976 | Bile secretion | 3.14E-03 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | | Lorpiprazole | hsa05010 | Alzheimer disease | 2.91E-03 | 7 | P13073, O75460, P0DP24, P01584, P18848, P67870, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, CSNK2B, SLC25A5 | More | | | Lorpiprazole | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | | Lorpiprazole | hsa05016 | Huntington disease | 3.74E-03 | 10 | O95298, P13073, P12074, P24928, P30876, P62487, P05141, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4, PSMD12 | More | | | Lorpiprazole | hsa05020 | Prion disease | 4.42E-04 | 10 | Q16718, O14521, P13073, Q92736, P18848, P05141, O60282, P49841, P67870, Q16539 | NDUFA5, SDHD, COX4I1, RYR2, ATF4, SLC25A5, KIF5C, GSK3B, CSNK2B, MAPK14 | More | | | Lorpiprazole | hsa05022 | Pathways of neurodegeneration - multiple diseases | 6.94E-04 | 13 | P49841, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, P0DP24 | GSK3B, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, CALM2 | More | | | Lorpiprazole | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Lorpiprazole | hsa05032 | Morphine addiction | 1.24E-02 | 5 | P62873, P50151, Q13370, P17252, P43250 | GNB1, GNG10, PDE3B, PRKCA, GRK6 | More | | | Lorpiprazole | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Lorpiprazole | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | | Lorpiprazole | hsa05110 | Vibrio cholerae infection | 4.65E-03 | 4 | Q13488, Q99437, P17252, P19174 | TCIRG1, ATP6V0B, PRKCA, PLCG1 | More | | | Lorpiprazole | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 8.57E-06 | 8 | Q16539, Q13153, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, PAK1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | | Lorpiprazole | hsa05130 | Pathogenic Escherichia coli infection | 4.08E-02 | 3 | Q15438, P35579, P55061 | PSCD1, MYH9, TEGT | More | | | Lorpiprazole | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | | Lorpiprazole | hsa05132 | Salmonella infection | 6.12E-04 | 13 | P51617, P25963, P01375, Q9UJU2, O00471, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, O60282, Q13509 | IRAK1, NFKBIA, TNF, LEF1, EXOC5, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, KIF5C, TUBB3 | More | | | Lorpiprazole | hsa05133 | Pertussis | 3.60E-03 | 1 | P0C0L4 | C4A | More | | | Lorpiprazole | hsa05134 | Legionellosis | 3.59E-04 | 7 | P01584, Q9NR31, P11215, P0DMV8, P11142, P09341, P19875 | IL1B, SAR1A, ITGAM, HSPA1A, HSPA8, CXCL1, CXCL2 | More | | | Lorpiprazole | hsa05135 | Yersinia infection | 3.95E-05 | 12 | Q05397, P51812, P13612, P06239, P19174, Q16539, Q02750, P42338, P49841, Q96JJ3, P01730, P01732 | PTK2, RPS6KA3, ITGA4, LCK, PLCG1, MAPK14, MAP2K1, PIK3CB, GSK3B, ELMO2, CD4, CD8A | More | | | Lorpiprazole | hsa05140 | Leishmaniasis | 9.33E-04 | 10 | O75015, P14598, P13765, O60603, P25963, P01375, P49006, Q16539, P51617, Q15080 | FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | | Lorpiprazole | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Lorpiprazole | hsa05144 | Malaria | 6.80E-05 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | | Lorpiprazole | hsa05145 | Toxoplasmosis | 4.33E-04 | 11 | P51617, P25963, P01375, P10415, Q13489, P42224, P13765, P09917, Q13751, P11142, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, STAT1, HLA-DOB, ALOX5, LAMB3, HSPA8, TLR2 | More | | | Lorpiprazole | hsa05146 | Amoebiasis | 6.60E-10 | 13 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | | Lorpiprazole | hsa05150 | Staphylococcus aureus infection | 1.48E-04 | 9 | P0C0L4, P21730, P21462, O75015, P13646, P59665, P59666, P12838, P49913 | C4A, C5AR1, FPR1, FCGR3B, KRT13, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | | | Lorpiprazole | hsa05152 | Tuberculosis | 9.13E-03 | 11 | Q13488, Q99437, P48382, O60603, P01375, P10415, P13765, P25774, P49913, Q9UDY8, P51617 | TCIRG1, ATP6V0B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CTSS, CAMP, MALT1, IRAK1 | More | | | Lorpiprazole | hsa05160 | Hepatitis C | 1.51E-04 | 9 | P52630, P60033, O00501, P29728, Q9NZJ5, P49841, P01375, P48023, P01106 | STAT2, CD81, CLDN5, OAS2, EIF2AK3, GSK3B, TNF, FASLG, MYC | More | | | Lorpiprazole | hsa05161 | Hepatitis B | 1.61E-03 | 10 | P17252, P14780, P25963, Q13485, P01375, P10415, P84022, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, SMAD4, TNF, BCL2, SMAD3, IRAK1, TLR2, STAT4 | More | | | Lorpiprazole | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | | Lorpiprazole | hsa05163 | Human cytomegalovirus infection | 6.30E-07 | 23 | P42338, P01375, P25963, P62873, P63218, P50151, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, P17252, Q13651, P25025, Q16539, P04637, O00463, P30101, P01568 | PIK3CB, TNF, NFKBIA, GNB1, GNG5, GNG10, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, PRKCA, IL10RA, CXCR2, MAPK14, TP53, TRAF5, PDIA3, IFNA21 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.736 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.754 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.926 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P0DP23 | CALM1 | Calmodulin-1 | 0.822 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.84 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.834 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 1 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.798 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.923 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | -0.713 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.799 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.892 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.786 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | 0.739 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | -0.721 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 |
| | Lorpiprazole | hsa05165 | Human papillomavirus infection | 2.26E-02 | 6 | Q16363, P30281, Q9UM47, P01889, P10321, Q99437 | LAMA4, CCND3, NOTCH3, HLA-B, HLA-C, ATP6V0B | More | | | Lorpiprazole | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.92E-04 | 13 | P01568, P42224, P25963, P42338, P40189, P62873, P62879, P50151, P19174, P16298, Q02750, P0DP23, P0CG47 | IFNA21, STAT1, NFKBIA, PIK3CB, IL6ST, GNB1, GNB2, GNG10, PLCG1, PPP3CB, MAP2K1, CALM1, UBB | More | | | Lorpiprazole | hsa05168 | Herpes simplex virus 1 infection | 6.31E-03 | 13 | P25963, P01568, P42224, Q07955, Q01130, Q13243, Q13489, P30101, P42338, Q13398, Q03923, O75820, Q9UDV6 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, PIK3CB, ZNF211, ZNF85, ZNF189, ZNF212 | More | | | Lorpiprazole | hsa05169 | Epstein-Barr virus infection | 1.07E-07 | 17 | P13765, P01106, Q13547, O00463, Q16539, P42338, P07948, P30101, Q13761, P24522, O75293, P01375, O60603, P29728, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, MAPK14, PIK3CB, LYN, PDIA3, RUNX3, GADD45A, GADD45B, TNF, TLR2, OAS2, CD3E, CD3G, CD247 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.738 | | Q04759 | PRKCQ | Protein kinase C theta type | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.82 | | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01106 | MYC | Myc proto-oncogene protein | 0.719 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.799 | | Q04759 | PRKCQ | Protein kinase C theta type | Q13547 | HDAC1 | Histone deacetylase 1 | 0.723 | | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Q13547 | HDAC1 | Histone deacetylase 1 | -0.774 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13547 | HDAC1 | Histone deacetylase 1 | 0.811 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q13547 | HDAC1 | Histone deacetylase 1 | -0.727 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.786 | | Q04759 | PRKCQ | Protein kinase C theta type | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.81 | | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.788 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 1 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.749 | | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.735 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | -0.721 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.744 | | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.708 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.793 | | Q04759 | PRKCQ | Protein kinase C theta type | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.846 | | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.768 | | Q04759 | PRKCQ | Protein kinase C theta type | P01375 | TNF | Tumor necrosis factor | -0.725 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60603 | TLR2 | Toll-like receptor 2 | 0.72 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P29728 | OAS2 | 2'-5'-oligoadenylate synthase 2 | -0.805 | | Q04759 | PRKCQ | Protein kinase C theta type | P29728 | OAS2 | 2'-5'-oligoadenylate synthase 2 | 0.875 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.77 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 |
| | Lorpiprazole | hsa05170 | Human immunodeficiency virus 1 infection | 4.49E-06 | 27 | P42338, P62873, P63218, P50151, P0DP23, P01375, P17252, O00463, P30101, Q14643, P01568, P01730, Q16539, P51617, P25963, O60603, Q13315, O95067, P19174, P23528, P07766, P09693, P20963, P10415, Q13619, Q93034, Q9Y6Q5 | PIK3CB, GNB1, GNG5, GNG10, CALM1, TNF, PRKCA, TRAF5, PDIA3, ITPR1, IFNA21, CD4, MAPK14, IRAK1, NFKBIA, TLR2, ATM, CCNB2, PLCG1, CFL1, CD3E, CD3G, CD247, BCL2, CUL4A, CUL5, AP1M2 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.736 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.754 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.926 | | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | | P08246 | ELA2 | Neutrophil elastase | P17252 | PRKCA | Protein kinase C alpha type | -0.735 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.786 | | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | 0.739 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | -0.721 | | P08246 | ELA2 | Neutrophil elastase | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.816 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | | P08246 | ELA2 | Neutrophil elastase | O60603 | TLR2 | Toll-like receptor 2 | 0.853 | | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | | P08246 | ELA2 | Neutrophil elastase | O95067 | CCNB2 | G2/mitotic-specific cyclin-B2 | 0.711 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P23528 | CFL1 | Cofilin-1 | -0.853 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | | P08246 | ELA2 | Neutrophil elastase | Q13619 | CUL4A | Cullin-4A | -0.707 | | P08246 | ELA2 | Neutrophil elastase | Q93034 | CUL5 | Cullin-5 | -0.744 | | P08246 | ELA2 | Neutrophil elastase | Q9Y6Q5 | AP1M2 | AP-1 complex subunit mu-2 | 0.811 |
| | Lorpiprazole | hsa05171 | Coronavirus disease - COVID-19 | 1.86E-04 | 18 | P25963, P42224, P01568, P23396, P62249, P42677, P40429, Q02878, P62917, P27635, P26373, Q07020, P46776, P05386, P40189, P42338, P19174, P17252 | NFKBIA, STAT1, IFNA21, RPS3, RPS16, RPS27, RPL13A, RPL6, RPL8, RPL10, RPL13, RPL18, RPL27A, RPLP1, IL6ST, PIK3CB, PLCG1, PRKCA | More | | | Lorpiprazole | hsa05200 | Pathways in cancer | 9.80E-05 | 21 | Q13751, P42338, P08238, P42224, P25963, P19174, P17252, P43246, P10826, P14923, Q13489, P49767, P14921, P62873, P50151, P78417, O75293, P0DP23, P01568, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, RARB, JUP, BIRC3, VEGFC, ETS1, GNB1, GNG10, GSTO1, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | | | Lorpiprazole | hsa05202 | Transcriptional misregulation in cancer | 1.40E-07 | 19 | Q12778, Q15532, Q13315, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P08069, P35226, P05164, P12838, P08246, Q9C0K0, Q13547, P24522 | FOXO1, SS18, ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC1, GADD45A | More | | | Lorpiprazole | hsa05203 | Viral carcinogenesis | 6.35E-03 | 7 | P30281, Q15283, P06396, P01889, P10321, P62807, O60814 | CCND3, RASA2, GSN, HLA-B, HLA-C, HIST1H2BC, H2BC12 | More | | | Lorpiprazole | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | | | Lorpiprazole | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | | | Lorpiprazole | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | | Lorpiprazole | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | | | Lorpiprazole | hsa05212 | Pancreatic cancer | 3.52E-02 | 2 | P84022, Q13485 | SMAD3, SMAD4 | More | | | Lorpiprazole | hsa05214 | Glioma | 4.14E-04 | 6 | P08069, P0DP23, P17252, P42338, P19174, O75293 | IGF1R, CALM1, PRKCA, PIK3CB, PLCG1, GADD45B | More | | | Lorpiprazole | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa05218 | Melanoma | 9.63E-04 | 4 | P08069, P09619, Q9GZP0, Q02750 | IGF1R, PDGFRB, PDGFD, MAP2K1 | More | | | Lorpiprazole | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | | Lorpiprazole | hsa05220 | Chronic myeloid leukemia | 1.25E-02 | 3 | Q13485, P25963, P84022 | SMAD4, NFKBIA, SMAD3 | More | | | Lorpiprazole | hsa05221 | Acute myeloid leukemia | 4.95E-02 | 3 | P42338, Q15744, P11215 | PIK3CB, CEBPE, ITGAM | More | | | Lorpiprazole | hsa05222 | Small cell lung cancer | 8.29E-05 | 10 | P10826, P42338, Q13751, Q13489, P10415, P25963, Q13077, O00463, P24522, O75293 | RARB, PIK3CB, LAMB3, BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A, GADD45B | More | | | Lorpiprazole | hsa05223 | Non-small cell lung cancer | 4.91E-03 | 5 | P17252, P42338, P19174, P10826, O75293 | PRKCA, PIK3CB, PLCG1, RARB, GADD45B | More | | | Lorpiprazole | hsa05224 | Breast cancer | 1.24E-02 | 5 | P08069, P49841, Q92837, P04637, P24522 | IGF1R, GSK3B, FRAT1, TP53, GADD45A | More | | | Lorpiprazole | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | | Lorpiprazole | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | | Lorpiprazole | hsa05231 | Choline metabolism in cancer | 1.66E-04 | 9 | Q02750, P42338, P09619, Q9GZP0, O15245, Q9Y259, P19174, P23743, P17252 | MAP2K1, PIK3CB, PDGFRB, PDGFD, SLC22A1, CHKB, PLCG1, DGKA, PRKCA | More | | | Lorpiprazole | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 5.25E-10 | 11 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, CD4 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P24723 | PRKCH | Protein kinase C eta type | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.727 | | Q04759 | PRKCQ | Protein kinase C theta type | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.733 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P24723 | PRKCH | Protein kinase C eta type | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.767 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.885 | | Q04759 | PRKCQ | Protein kinase C theta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.713 | | P24723 | PRKCH | Protein kinase C eta type | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.887 | | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.823 | | Q04759 | PRKCQ | Protein kinase C theta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.92 | | P24723 | PRKCH | Protein kinase C eta type | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.939 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.804 | | Q04759 | PRKCQ | Protein kinase C theta type | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.756 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.744 | | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.835 | | Q04759 | PRKCQ | Protein kinase C theta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.779 | | P24723 | PRKCH | Protein kinase C eta type | P06239 | LCK | Tyrosine-protein kinase Lck | 0.912 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O60603 | TLR2 | Toll-like receptor 2 | 0.73 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60603 | TLR2 | Toll-like receptor 2 | 0.72 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | | Q04759 | PRKCQ | Protein kinase C theta type | Q04759 | PRKCQ | Protein kinase C theta type | 1 | | P24723 | PRKCH | Protein kinase C eta type | Q04759 | PRKCQ | Protein kinase C theta type | 0.791 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.842 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | | P11169 | SLC2A3 | Solute carrier family 2, facilitated glucose transporter member 3 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.766 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.707 | | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 |
| | Lorpiprazole | hsa05310 | Asthma | 9.97E-04 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | | Lorpiprazole | hsa05321 | Inflammatory bowel disease | 8.42E-08 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | | Lorpiprazole | hsa05322 | Systemic lupus erythematosus | 2.09E-04 | 12 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | | Lorpiprazole | hsa05323 | Rheumatoid arthritis | 4.95E-02 | 3 | Q06643, P09341, P19875 | LTB, CXCL1, CXCL2 | More | | | Lorpiprazole | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Lorpiprazole | hsa05332 | Graft-versus-host disease | 1.89E-09 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | | Lorpiprazole | hsa05340 | Primary immunodeficiency | 2.93E-04 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | | Lorpiprazole | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.71E-03 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | | Lorpiprazole | hsa05414 | Dilated cardiomyopathy | 2.58E-03 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | | Lorpiprazole | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | | Lorpiprazole | hsa05418 | Fluid shear stress and atherosclerosis | 1.26E-04 | 8 | Q16539, Q14145, P10599, P14780, P01375, P04637, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2 | More | |
|
